Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by RBA Wealth Management LLC

RBA Wealth Management LLC raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,331 shares of the medical instruments supplier’s stock after acquiring an additional 604 shares during the quarter. Becton, Dickinson and Company makes up 1.8% of RBA Wealth Management LLC’s portfolio, making the stock its 23rd biggest position. RBA Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $4,839,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Livelsberger Financial Advisory acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter valued at about $26,000. Ashton Thomas Securities LLC acquired a new stake in shares of Becton, Dickinson and Company in the third quarter valued at approximately $33,000. Tompkins Financial Corp boosted its stake in shares of Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the last quarter. Sound Income Strategies LLC raised its position in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 44 shares during the period. Finally, Kennebec Savings Bank acquired a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at approximately $46,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have commented on BDX. Piper Sandler boosted their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Moderate Buy” and an average target price of $283.00.

Insider Buying and Selling

In other news, EVP David Shan sold 500 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the sale, the executive vice president now owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. The trade was a 8.01 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Roland Goette sold 638 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $219.03, for a total value of $139,741.14. Following the completion of the transaction, the executive vice president now owns 14,217 shares of the company’s stock, valued at approximately $3,113,949.51. The trade was a 4.29 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 9,844 shares of company stock worth $2,210,716. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.0 %

Shares of BDX stock opened at $247.57 on Tuesday. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $251.99. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. The stock has a market cap of $71.80 billion, a price-to-earnings ratio of 41.68, a PEG ratio of 1.80 and a beta of 0.40. The stock has a 50-day moving average of $230.53 and a 200-day moving average of $233.83.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the firm posted $3.42 earnings per share. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. On average, equities research analysts forecast that Becton, Dickinson and Company will post 14.41 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 1.68%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is 70.03%.

Becton, Dickinson and Company announced that its board has approved a share repurchase program on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.